CD274 and neoplasm: In the case of a PD-L1-negative tumor with a CPS of 0, the combination of trastuzumab with a chemotherapy regimen comprising a fluoropyrimidine and a platinum derivative remains the preferred treatment option, as demonstrated in the ToGA study [32].